Meredith Cook Sells 500 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 500 shares of the business’s stock in a transaction dated Monday, April 13th. The shares were sold at an average price of $77.95, for a total transaction of $38,975.00. Following the transaction, the vice president directly owned 78,890 shares of the company’s stock, valued at $6,149,475.50. The trade was a 0.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Meredith Cook also recently made the following trade(s):

• On Friday, March 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $72.62, for a total transaction of $36,310.00.
• On Tuesday, January 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $84.33, for a total transaction of $42,165.00.

ANI Pharmaceuticals Price Performance

NASDAQ ANIP opened at $78.29 on Wednesday. ANI Pharmaceuticals, Inc. has a 12 month low of $56.71 and a 12 month high of $99.50. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.71 and a quick ratio of 2.19. The firm has a market capitalization of $1.75 billion, a PE ratio of 23.30 and a beta of 0.44. The company’s 50 day simple moving average is $76.32 and its 200 day simple moving average is $82.14.

Institutional Trading of ANI Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. GAMMA Investing LLC raised its holdings in shares of ANI Pharmaceuticals by 9.1% in the 3rd quarter. GAMMA Investing LLC now owns 1,505 shares of the specialty pharmaceutical company’s stock worth $138,000 after purchasing an additional 126 shares in the last quarter. Maryland State Retirement & Pension System raised its holdings in shares of ANI Pharmaceuticals by 5.4% in the 4th quarter. Maryland State Retirement & Pension System now owns 2,613 shares of the specialty pharmaceutical company’s stock worth $206,000 after purchasing an additional 134 shares in the last quarter. Illinois Municipal Retirement Fund raised its holdings in shares of ANI Pharmaceuticals by 1.7% in the 3rd quarter. Illinois Municipal Retirement Fund now owns 8,538 shares of the specialty pharmaceutical company’s stock worth $782,000 after purchasing an additional 145 shares in the last quarter. Amalgamated Bank raised its holdings in shares of ANI Pharmaceuticals by 3.1% in the 3rd quarter. Amalgamated Bank now owns 5,066 shares of the specialty pharmaceutical company’s stock worth $464,000 after purchasing an additional 154 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co raised its holdings in shares of ANI Pharmaceuticals by 1.0% in the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company’s stock worth $1,267,000 after purchasing an additional 198 shares in the last quarter. 76.05% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on ANIP shares. Wall Street Zen lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, March 14th. Weiss Ratings reiterated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research note on Monday, December 29th. Guggenheim raised their price objective on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a research note on Friday, January 16th. Finally, Zacks Research lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Five equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, ANI Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $107.33.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.